Nuvation Bio Inc. (NUVB)
NYSE: NUVB
· Real-Time Price · USD
2.27
0.07 (3.18%)
At close: May 29, 2025, 3:59 PM
2.24
-1.10%
After-hours: May 29, 2025, 07:57 PM EDT
3.18% (1D)
| Bid | 2.24 |
| Market Cap | 768.43M |
| Revenue (ttm) | 10.96M |
| Net Income (ttm) | -606.38M |
| EPS (ttm) | -2.2 |
| PE Ratio (ttm) | -1.03 |
| Forward PE | -3.48 |
| Analyst | Buy |
| Ask | 2.28 |
| Volume | 5,563,185 |
| Avg. Volume (20D) | 3,462,600 |
| Open | 2.22 |
| Previous Close | 2.20 |
| Day's Range | 2.18 - 2.27 |
| 52-Week Range | 1.54 - 3.97 |
| Beta | 1.42 |
About NUVB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NUVB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NUVB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+14.44%
Nuvation Bio shares are trading higher after RBC C...
Unlock content with
Pro Subscription
9 months ago
-5.36%
Nuvation Bio shares are trading lower. The company reported Q2 financial results.
3 weeks ago · seekingalpha.com
Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer SubtypesNuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate, and FDA approval is likely by June 2025. Financially robust, Nuvation Bio has over three years of...
